Navigation Links
China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
Date:9/10/2008

HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully developed 26 new drugs that are currently in clinical trials.

Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned subsidiary of China Sky One Medical, recently completed research and development for the 26 new drugs, which have been submitted to the State Food and Drug Administration (SFDA) in the PRC for approval.

-- Four drugs, including Cleaning suppositories, Tinidazole

suppositories, Policresulen vaginal suppositories, and Aciclover gel

are for the treatment of vaginits;

-- Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium

Chloride and Compound Chlorhexidine, are gargles for the treatment

of toothache;

-- Three drugs, including Diclofenac Sodium Suppositories, Paediatric

Ibuprofen suppositories and Musky cream, are for pain relief;

-- Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture

and Nitrofurantoin suppositories, are anti-infectives;

-- Two drugs, including Collunarium and Compound Naphazoline Spray, are

for the treatment of rhinopathy;

-- Two drugs, including Sulfasalazine suppositories and Sodium ferulate

injection are for the treatment of cardiovascular disease;

-- Methionine Vitamin B1 injection is for improving liver function;

-- Doxofylline injection is for the treatment of asthma;

-- Pantoprazole sodium injection is for the treatment of canker sores;

-- Calcium Folinate injection is intended as an antidote for folic acid

deficiency;

-- Hydrastis suppositories are for the treatment of colds; and

-- The final four drugs, including hemorrhoids gel, hemorrhoids liquids,

chilblain cream and expectorant, are all externally used.

"We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over- the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
6. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
Breaking Medicine Technology:
(Date:5/28/2016)... , ... May 28, 2016 , ... "Color Grading media ... and drop a preset onto their media," said Christina Austin - CEO of Pixel ... editors can quickly and easily add stylish color grades to their footage. A LUT ...
(Date:5/28/2016)... ... ... After a year and a half of planning the Multiple Pathways of Recovery Conference ... of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel ... to explore the many pathways individuals use to get into and sustain their recovery. ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... An influential ... for a third time to shed lights on the variety of topics detailing why ... stories, “Nurse Appreciation” tackles why this career has gone from being in a major ...
Breaking Medicine News(10 mins):